KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Payables (2016 - 2025)

NovoCure's Payables history spans 12 years, with the latest figure at $122.2 million for Q4 2025.

  • For Q4 2025, Payables fell 81.57% year-over-year to $122.2 million; the TTM value through Dec 2025 reached $122.2 million, down 81.57%, while the annual FY2025 figure was $122.2 million, 81.57% down from the prior year.
  • Payables for Q4 2025 was $122.2 million at NovoCure, down from $679.5 million in the prior quarter.
  • Across five years, Payables topped out at $679.5 million in Q3 2025 and bottomed at $52.7 million in Q1 2021.
  • The 5-year median for Payables is $83.4 million (2023), against an average of $224.9 million.
  • The largest annual shift saw Payables soared 714.19% in 2024 before it plummeted 81.57% in 2025.
  • A 5-year view of Payables shows it stood at $72.6 million in 2021, then rose by 17.35% to $85.2 million in 2022, then grew by 10.79% to $94.4 million in 2023, then soared by 602.66% to $663.2 million in 2024, then tumbled by 81.57% to $122.2 million in 2025.
  • Per Business Quant, the three most recent readings for NVCR's Payables are $122.2 million (Q4 2025), $679.5 million (Q3 2025), and $663.5 million (Q2 2025).